Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
April 29 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, today announced the presentation of two poster abstracts
at the upcoming American Society of Clinical Oncology (ASCO) 2022
Annual Meeting, to be held in-person on June 3-7, 2022 in Chicago,
Illinois. Notably, abstract number 4511 was selected for an oral
presentation as part of a Poster Discussion Session.
|
|
Abstract Title: |
A
Phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with
cabozantinib in patients with advanced or metastatic clear cell
renal cell (ccRCC) carcinoma who have received front-line treatment
(NCT04300140) |
Abstract
Number: |
4511 (Poster Discussion Session –
Data will be presented) |
Poster
Session: |
Genitourinary Cancer—Kidney and
Bladder |
Session
Date: |
Saturday, June 4, 2022, 4:30
PM-6:00 PM; 1:15 PM-4:15 PM CDT |
Abstract Title: |
A
Phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with
cabozantinib, cabozantinib and nivolumab, and as monotherapy in
patients with advanced or metastatic clear cell renal cell
carcinoma (NCT04300140) |
Abstract
Number: |
TPS4599 (Trials in Progress
poster – No data presented) |
Poster
Session: |
Genitourinary Cancer—Kidney and
Bladder |
Session
Date: |
Saturday, June 4, 2022, 1:15
PM-4:15 PM CDT |
|
|
Both posters will be available here:
https://aravive.com/our-approach/ under the “Publications” section
when the ASCO embargo is released on May 26, 2022 at
4:00 PM CDT.
About AraviveAravive, Inc. is a
late clinical-stage oncology company developing targeted
therapeutics to treat metastatic disease. Our lead product
candidate, batiraxcept (formerly AVB-500), is an ultra-high
affinity decoy protein that binds to GAS6, the sole ligand that
activates AXL, thereby inhibiting metastasis and tumor growth, and
restoring sensitivity to anti-cancer agents. Batiraxcept has been
granted Fast Track Designation by the U.S. FDA and Orphan Drug
Designation by the European Commission in platinum-resistant
recurrent ovarian cancer. Batiraxcept is in an active
registrational Phase 3 trial in platinum resistant ovarian cancer
(NCT04729608), a Phase 1b/2 trial in clear cell renal cell
carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic
adenocarcinoma (NCT04983407). Additional information at
www.aravive.com.
Contact:Marek Ciszewski, J.D.Vice President,
Investor RelationsMarek@Aravive.com(562) 373-5787
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024